Tsukuba Research Center
In August 2009, the company established the Tsukuba Research Center, which conducts molecular- targeted drug research, aiming to create a research system focused on trends in new medical treatment, including the personalized medical care that has been making progress in recent years. Tsukuba Research Center discovers new drug candidates in oncology, allergy/immunology, and urology. Tsukuba Research Center, Tokushima Research Center, and Clinical Development Center form a seamlessly connected research network.
Tokushima Research Center
Tokushima Research Center pursues efficacy, safety, and commercialization technologies to advance drug candidates from clinical trials to medicines that contribute to patient care.
Tokushima Clinical Development Center
The Clinical Development Center shepherds compounds through all phases of the clinical trial and development process and participates in disseminating safety and use information to healthcare professionals and in global drug development.
Tokushima Plant
The Tokushima Plant consists of 10 manufacturing facilities. It manufactures pharmaceuticals and quasi-drugs in a variety of formulations, including tablets, capsules, granules, injections, and drinks.
Okayama Plant
The Okayama Plant manufactures the Tiovita® multivitamin nutrient tonic series
Saitama Plant
The Saitama Plant manufactures bulk drugs (the active ingredients for TS-1, UFT, and IPD).
Inuyama Plant
The Inuyama Plant mainly manufactures crude drugs for the Harncare (herbal medicine for mild incontinence/frequency) line.